TNFRSF17 and plasma cell myeloma: The pooled CRS rate in studies using BCMA.CD3 structure (56.7%, 95% CI 47.2–66.0%) was lower than studies targeting myeloma cells through receptors other than BCMA (68.1%, 95% CI 62.8–73.1%).